Linda Skalsky
Psychiatric/Mental Health · Gainesville, FLNPI 1194837989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,855 of the $52,577 with a category attached, or 72.0%. AbbVie accounts for 72.3% of it on its own, with 14 other manufacturers making up the rest. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $130.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$605
- Teva Pharmaceuticals USA, Inc.$556
- Otsuka America Pharmaceutical, Inc.$382
- plus $1K from 9 others
What the payments were for
- Consulting fees$3,8757%
- Speaking & faculty fees$37,85572%
- Travel & lodging$3,3046%
- Food & beverage$7,49714%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 159 | $37,990 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $10,655 |
| Alkermes, Inc. | 41 | $1,086 |
| Vanda Pharmaceuticals Inc. | 24 | $605 |
| Teva Pharmaceuticals USA, Inc. | 38 | $556 |
| Otsuka America Pharmaceutical, Inc. | 12 | $382 |
| Neurocrine Biosciences, Inc. | 16 | $378 |
| Sunovion Pharmaceuticals Inc. | 28 | $358 |
| E.r. Squibb & Sons, L.L.C. | 13 | $349 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Braeburn Inc. | 2 | $46 |
| Indivior Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $30 |
| Lundbeck LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$35,072
- CAPLYTA$9,459
- ARISTADA$474
- LYBALVI$400
- COBENFY$132
- ARISTADA INITIO$118
- ABILIFY MAINTENA$117
- Fanapt$108
How this compares
$52,577 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 94 | $142,767 |
| Invega SustennaPaliperidone Palmitate | 36 | $119,883 |
| AustedoDeutetrabenazine | 16 | $106,270 |
| Risperdal ConstaRisperidone Microspheres | 12 | $15,636 |
| Aripiprazole | 85 | $7,077 |
| Lurasidone Hcl | 80 | $6,898 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $4,121 |
| Quetiapine Fumarate | 134 | $3,708 |
| Ziprasidone Hcl | 19 | $2,923 |
| Olanzapine | 120 | $2,607 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 48 | $2,389 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $2,020 |
| Benztropine Mesylate | 112 | $1,715 |
| Bupropion XlBupropion Hcl | 80 | $1,513 |
| Clozapine | 23 | $1,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $37,990 | $142,76794 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $30 | $135,51948 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $556 | $106,27016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Gainesville
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.